Ross A. Soo | Scholar Profiles and Rankings

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK + non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. (journal article) Solomon, Benjamin J. \| Liu, Geoffrey \| Felip, Enriqueta \| Mok, Tony S. K. \| Soo, Ross Andrew \| Mazieres, Julien \| Shaw, Alice Tsang \| de Marinis, Filippo \| Goto, Yasushi \| Wu, Yi-Long \| ... \| Bauer, Todd Michael Journal of Clinical Oncology, volume 42, issue 17_suppl, pages LBA8503-LBA8503 (2024). 10.1200/JCO.2024.42.17_suppl.LBA8503 Cite \| Source
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) muta (journal article) Johnson, Melissa Lynne \| Soo, Ross A. \| Wu, Yi-Long \| Baktash, Navid \| Maier, Daniela \| Eigenbrod-Giese, Sabina \| Yoshida, Tatsuya Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS8654-TPS8654 (2024). 10.1200/JCO.2024.42.16_suppl.TPS8654 Cite \| Source
A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide. (journal article) Lee, Matilda \| Ow, Samuel Guan Wei \| Wong, Andrea \| Lim, Siew Eng \| Lim, Joline Si Jing \| Soo, Ross A. \| Cheng Ean, Chee \| Tan, David Shao Peng \| Yong, Wei Peng \| Chan, Gloria Hui Jia \| ... \| Lee, Soo-Chin Journal of Clinical Oncology, volume 42, issue 16_suppl, pages e14507-e14507 (2024). 10.1200/JCO.2024.42.16_suppl.e14507 Cite \| Source
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study (journal article) Solomon, Benjamin J. \| Liu, Geoffrey \| Felip, Enriqueta \| Mok, Tony S.K. \| Soo, Ross A. \| Mazieres, Julien \| Shaw, Alice T. \| de Marinis, Filippo \| Goto, Yasushi \| Wu, Yi-Long \| ... \| Bauer, Todd M. Journal of Clinical Oncology (2024). 10.1200/JCO.24.00581 Cited by (10) \| Cite \| Source
International Cost-Effectiveness Analysis of Durvalumab in Stage III Non–Small Cell Lung Cancer (journal article) Kareff, Samuel A. \| Han, Sunwoo \| Haaland, Benjamin \| Jani, Chinmay J. \| Kohli, Rhea \| Aguiar, Pedro Nazareth \| Huang, Yiqing \| Soo, Ross A. \| Rodríguez-Perez, Ángel \| García-Foncillas, Jesús \| ... \| de Lima Lopes, Gilberto JAMA Network Open, volume 7, issue 5, pages e2413938- (2024). 10.1001/jamanetworkopen.2024.13938 Cite \| Source
102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (T (journal article) Wu, Y-L. \| Johnson, M.L. \| Soo, R.A. \| Baktash, N. \| Maier, D. \| Eigenbrod-Giese, S. \| Yoshida, T. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.102681 Cite \| Source
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer (journal article) Chen, Joseph \| Bearz, Alessandra \| Kim, Dong-Wan \| Mamdani, Hirva \| Bauman, Jessica \| Chiari, Rita \| Ou, Sai-Hong Ignatius \| Solomon, Benjamin J. \| Soo, Ross A. \| Felip, Enriqueta \| ... \| Pithavala, Yazdi K. Clinical Pharmacokinetics, volume 63, issue 2, pages 171-182 (2024). 10.1007/s40262-023-01309-4 Cite \| Source
43O A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors (journal article) Santa Gadea, O. Saavedra \| Machiels, J-P. \| Soo, R.A. \| Wong, M. \| Ma, B.B.Y. \| Zander, T. \| Wang, Y. \| Lin, J.J. \| Gambardella, V. \| Zhao, J. \| ... \| Yamamoto, N. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.102272 Cite \| Source
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report (journal article) Mirza, Myriam \| Shrivastava, Aseem \| Matthews, Cecile \| Leighl, Natasha \| Ng, Calvin S. H. \| Planchard, David \| Popat, Sanjay \| Rotow, Julia \| Smit, Egbert F. \| Soo, Ross \| ... \| Wu, Yi-Long Frontiers in Oncology, volume 13 (2024). 10.3389/fonc.2023.1330468 Cite \| Source
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection (journal article) Soo, Ross Andrew \| de Marinis, Filippo \| Han, Ji-Youn \| Ho, James Chung-Man \| Martin, Emma \| Servidio, Leslie \| Sandelin, Martin \| Popat, Sanjay Clinical Lung Cancer, volume 25, issue 1, pages 80-84 (2024). 10.1016/j.cllc.2023.09.005 Cited by (4) \| Cite \| Source
Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer (journal article) Lim, Sun Min \| Lee, Jii Bum \| Oya, Yuko \| Nutzinger, Jorn \| Soo, Ross JCO Oncology Practice, volume 20, issue 1, pages 47-56 (2024). 10.1200/OP.23.00273 Cited by (4) \| Cite \| Source
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future (journal article) Nützinger, Jorn \| Bum Lee, Jii \| Li Low, Jia \| Ling Chia, Puey \| Talisa Wijaya, Silvana \| Chul Cho, Byoung \| Min Lim, Sun \| Soo, Ross A Lung Cancer, volume 186 (2023). 10.1016/j.lungcan.2023.107385 Cited by (4) \| Cite \| Source
Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting? (journal article) Ang, Yvonne L.E. \| Soo, Ross A. Journal of Thoracic Oncology, volume 18, issue 12, pages 1621-1624 (2023). 10.1016/j.jtho.2023.09.1438 Cite \| Source
482P Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort (journal article) Chia, P.L. \| Kit Chung, J.T. \| Asmat, A. \| Huggenberger, R. \| Verma, A. \| Soo, R.A. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.10.556 Cite \| Source
596P Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial (journal article) Lu, S. \| Hu, X. \| Kim, S-W. \| Goto, K. \| Yang, N. \| Soo, R.A. \| Fang, J. \| Yao, W. \| Lee, K.H. \| Lim, D.W-T. \| ... \| Cho, B.C. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.10.674 Cite \| Source
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC (journal article) Soo, Ross A. \| Martini, Jean-François \| van der Wekken, Anthonie J. \| Teraoka, Shunsuke \| Ferrara, Roberto \| Shaw, Alice T. \| Shepard, Deborah \| Calella, Anna Maria \| Polli, Anna \| Toffalorio, Francesca \| ... \| Solomon, Benjamin J. Journal of Thoracic Oncology, volume 18, issue 11, pages 1568-1580 (2023). 10.1016/j.jtho.2023.05.021 Cited by (14) \| Cite \| Source
EP06.03-10 HER3 Expression in Archived Tissue Samples from Patients with NSCLC Across Various Genomic Subtypes and Characteristics (journal article) Soo, R. \| Phani, S. \| Wu, C. \| Diamand, F. \| Fan, P.-D. \| Patel, P. \| Bubendorf, L. Journal of Thoracic Oncology, volume 18, issue 11, pages S486- (2023). 10.1016/j.jtho.2023.09.902 Cite \| Source
P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC (journal article) Soo, R. \| De Marinis, F. \| Han, J.-Y. \| Ho, C.M.J. \| Lin, Y. \| Servidio, L. \| Sandelin, M. \| Popat, S. Journal of Thoracic Oncology, volume 18, issue 11, pages S272- (2023). 10.1016/j.jtho.2023.09.463 Cite \| Source
P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR (journal article) Dao, T.V. \| Soo, R.A. \| Batra, U. \| Tamayo, M.B.E. \| Tejado Gallegos, L.F. \| Donner, N. \| Alsayed, M. \| Huggenberger, R. \| Reungwetwattana, T. Journal of Thoracic Oncology, volume 18, issue 11, pages S271- (2023). 10.1016/j.jtho.2023.09.461 Cite \| Source
MA10.03 A Cost-Effectiveness Analysis of Actionable Genomic Alteration (AGA) Testing Strategies in Non-Small Cell Lung Cancer (NSCLC) (journal article) Ang, Y. \| Ong, M.J.C. \| Wang, N. \| Rozali, E. \| Gibbs, M. \| Soo, R.A. Journal of Thoracic Oncology, volume 18, issue 11, pages S133- (2023). 10.1016/j.jtho.2023.09.181 Cite \| Source